Skip to main content
Scholars@Duke
Menu
About
Schools / Institutes
Browse
Rabina Kochar Walsh
Assistant Professor of Dermatology
Dermatology
5324 McFarland Dr, Suite 410, Durham, NC 27707
Research
More About This Person
glance {hide_children: true, active: false, enabled: true}
At a Glance
credentials {hide_children: true, active: false, enabled: true}
Credentials
Education
Training & Certifications
Medical Licensure
academic-experience {hide_children: true, active: false, enabled: true}
Academic Experience
Current Appointments & Affiliations
Previous Appointments & Affiliations
Leadership & Clinical Positions
expertise {hide_children: true, active: false, enabled: false}
Expertise
research {hide_children: false, active: true, enabled: true}
Research
Selected Grants
publications {hide_children: true, active: false, enabled: true}
Publications
Selected Publications
artistic-works {hide_children: true, active: false, enabled: false}
Artistic Works / Events
teaching {hide_children: true, active: false, enabled: false}
Teaching
advising-mentoring {hide_children: true, active: false, enabled: true}
Advising & Mentoring
Advising & Mentoring
recognition {hide_children: true, active: false, enabled: false}
Recognition
professional-activities {hide_children: true, active: false, enabled: true}
Professional Activities
Selected Presentations & Appearances
Service to the Profession
Manage Profile
Embed Profile Data
Manage Profile
Embed Profile Data
Selected Grants
A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)(ROCKET-ASCEND)
Clinical Trial
Principal Investigator ·
Awarded by Amgen, Inc. ·
2023 - 2028
A Phase 3, Randomized, 52-week, Placebo-controlled, Double-blind Study With Rerandomization to Assess the Efficacy, Safety, and Tolerability of Rocatinlimab (AMG 451) in Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD)-ROCKET-ASTRO
Clinical Trial
Principal Investigator ·
Awarded by Amgen, Inc. ·
2023 - 2026
A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)
Clinical Trial
Principal Investigator ·
Awarded by Amgen, Inc. ·
2023 - 2024
